Inhibitor

(redirected from alpha1-proteinase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Legal.

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
References in periodicals archive ?
Alpha1-antitrypsin deficiency, also known as AAT deficiency or alpha-1, is an inherited disorder that causes significant reduction in the naturally occurring protein alpha1-proteinase inhibitor.
Important Safety Information PROLASTIN, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic augmentation and maintenance therapy of individuals having congenital deficiency of alpha1- PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema.
About Alpha1-Antitrypsin Deficiency Alpha1-antitrypsin deficiency, also known as AAT deficiency or Alpha-1, is an inherited disorder that causes significant reduction in the naturally occurring protein alpha1-proteinase inhibitor .
Food and Drug Administration (FDA) for use as chronic augmentation and maintenance therapy in adults with alpha1-proteinase inhibitor deficiency (Alpha-1), a life threatening genetic disorder, which clinically manifests as emphysema.